POST Online Media Lite Edition



 

NEWLY REPORTED COVID-19 CASES IN LAST 24 HOURS (4.15.2021, 1:40pm CEST, WHO):   U.S. 78,134    India 200,739    Brazil 82,186    France 38,956    Russia 8,326    The United Kingdom 2,471    Turkey 59,187    Italy 13,439    Germany 21,693    Poland 21,266    Argentina 27,001    Columbia 16,377    Mexico 4,293    Iran 25,582    Ukraine 14,553    Peru 6,387    Czechia 5,087    Indonesia 5,656    South Africa 1,599    The Netherlands 6,797    Chile 5,557    Canada 7,546    Romania 3,883    Iraq 7,972    Philippines 8,122    Sweden 3,471    Pakistan 4,503    Hungary 3,597    Bangladesh 5,185    Jordan 4,085    Serbia 3,572    Austria 2,032    Japan 3,952    Lebanon 2,460    United Arab Emirates 1,798    Bulgaria 2,944    Slovakia 1,069    Malaysia 1,889    Ecuador 2,950    Palestine 1,923    Greece 4,017    Croatia 3,099    Georgia 1,085    Azerbaijan 2,457    Bolivia 1,099    Tunisia 2,123    Kuwait 1,402    Paraguay 2,599    Ethiopia 1,893    Lithuania 1,371    Slovenia 1,049    Armenia 1,075    Venezuela 1,160    Oman 1,269    Bahrain 1,175    Uruguay 2,257    North Macedonia 1,128    Thailand 1,335    Mongolia 1,220    China 20    Singapore 27    New Zealand 2    Australia 14    South Korea 698   

Proton therapy offers new treatment for recurrent lung cancer

Staff Writer |
A new study offers hope for patients with recurrent lung cancer, who historically have been considered ineligible for curative treatment.

Article continues below






In the largest analysis to date of reirradiation using intensity-modulated proton therapy (IMPT) for lung and other thoracic tumors, more than three-fourths of patients were free from local recurrence at one year following retreatment, and fewer than one in ten patients experienced severe side effects.

Lung cancer causes more deaths in the United States than any other type of cancer, due in part to its aggressive nature and likelihood of recurrence.

Historically, recurrences have been challenging to treat, because many of these patients are not candidates for surgery.

Moreover, concerns about cumulative radiation doses to essential organs near thoracic tumors (e.g., heart, lungs, esophagus) may limit the use of curative radiation therapy (RT) for patients who received thoracic RT in the past.

Accordingly, patients whose lung cancer recurs are generally offered only palliative options to manage pain and other symptoms.

Proton therapy, an advanced type of RT, allows radiation oncologists to spare critical normal tissues while delivering escalated, curative doses of radiation to nearby tumors.

In particular, IMPT is able to exactly target a tumor, even if the tumor wraps around a critical normal tissue structure, such as a lung.

Researchers retrospectively examined the records of 27 patients who received reirradiation for thoracic tumors using the IMPT technique through prospective clinical trials at a single institution between 2011 and 2016.

Twenty-two patients (81%) had non-small cell lung cancer (NSCLC). All patients had previously received curative thoracic RT.

Time to reirradiation ranged from 0.1 months to 212 months, with a median of 29.5 months. The median radiation dose was 66 Gray (Gy), with a range of 43.2 to 84 Gy, and it was delivered in 2 Gy fractions. The median follow-up for all patients in the study was 11.2 months.

The median overall survival (OS) for patients in this study was 18 months following IMPT reirradiation. At one year following retreatment, the majority of patients were free from local and regional relapse.

Just over half of the patients were free from disease progression and the one-year OS rate was 54 percent. Four of the patients (15%) experienced a local recurrence within one year of retreatment.

Patients who were prescribed a higher dose of IMPT reirradiation were even less likely to experience recurrence or progression.

At one-year follow-up, patients who received IMPT reirradiation doses at or above the population median were twice as likely to be free from local failure and nearly four times as likely to be free from local-regional failure.

Reirradiation with IMPT was well-tolerated among the patients. Only two patients (7%) experienced moderate to severe long-term lung toxicity (i.e., grade 3 or higher side effects).

There were no severe long-term esophageal side effects nor any life-threatening toxicities among these patients.


What to read next

AstraZeneca: Tagrisso could replace chemo for some
New drug to treat lung cancer in sight
Brain cancer treatment shows promise in early trial